ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NCI funds nine centers for $14.9 million integrative biology program.

October 29, 2004

NCI Funds Proteomic Technology Assessment Grants.

September 29, 2006

Duke Promised $11.5M For Eye, Lung Research.

March 8, 2002

Drugs Available To Investigators Centers to Monitor Them Are Listed

September 9, 1977

New CCOP RFA Available; Briefing At ASCO Jammed

June 2, 1989

Biomed Research Absent from Bush State of the Union.

January 26, 2007